Create a free account, or log in

Inspired by insect ears: Medtech Hemideina secures $1 million to develop teeny, tiny alternative hearing device

Medtech startup Hemideina has raised $1 million to develop and commercialise its hearing aid solution inspired by the auditory systems of insects.
Hemideina
Hemideina founders Liz Williams and Kate Lomas. Source: supplied.

Melbourne-based medtech startup Hemideina has raised $1 million in Series A funding to develop and commercialise an alternative hearing aid solution inspired by the auditory systems of insects.

Hemideina was founded in February 2017 by research scientists Dr Kate Lomas and Dr Elizabeth Williams, after the pair won Australiaโ€™s MedTechโ€™s Got Talent competition and completed its accelerator program, securing a total of $60,000 in seed funding.

Born out of Lomasโ€™s PhD research into insect acoustic systems, the startup is developing its Hera Wireless Implant device, made up of a 15mm by 10mm in-ear bud, and an electrode implanted into the cochlea.

Speaking to StartupSmart, Williams explained the technology takes inspiration from the New Zealand native hemideina crassidens, or the Wellington tree weta, which can hear in the same auditory range as humans.

โ€œItโ€™s a tiny species, so we realised we could miniaturise the current cochlea implant system by taking inspiration from this system, as to how it processes sound.โ€

The focus of every conversation

The startup is still in early stages, but the founders have run workshops with children using traditional cochlea implants or hearing aids, and found thereโ€™s a demand for a less cumbersome device.

โ€œWeโ€™re working with users to make sure the device remains very much patient-focused,โ€ Williams says.

Current solutions can fall off while kids are running or playing, Williams explains, but theyโ€™re also very much visible.

Through workshopping the idea with the children, the team found โ€œpeople always start a conversation with them around their cochlea implants, because itโ€™s the first thing they noticeโ€, Williams says.

โ€œIt would be amazing for someone not to know, and for that not to be the focus of every conversation.โ€

Hemideina’s Hera device is designed to be so tiny โ€œyou wonโ€™t be able to identify the userโ€™s disabilityโ€, she adds.

However, through their market research, the founders also discovered some demands they didnโ€™t know about, Williams says.

โ€œSome of them quite enjoy trying to turn their implants off โ€ฆ so that was something we knew we might have to build into the design.โ€

An underserved market

The $1 million in funding came from angel investors and high-net-worth individuals, Williams says.

Mainly, it will be used for manufacturing and testing the prototype and onboarding people to help the scientific founders with the hardware and electronics aspects of the technology.

โ€œThatโ€™s really the focus of the next 12 months.โ€

It will also be used to help the team work on the regulatory side of things, โ€œto ensure weโ€™re fully compliant as we move forwardโ€, Williams says.

โ€œWeโ€™re in the highest risk class because weโ€™ve got the implantable side, so we have to be quite stringent with all the testing and clinical trials,โ€ she adds.

Regulation and policy is not something the founders have come across in their research careers, Williams says, and theyโ€™ve found that in this space, โ€œthat really does pretty much define your development pathโ€.

Any medical device has to fit the regulation and meet the clinical need.

โ€œFrom that, you map out what your device needs to have and the specifications,โ€ Williams explains.

โ€œItโ€™s a nice structure, but learning it for the first time is definitely a lot of work,โ€ she adds.

Ultimately, Williams doesnโ€™t expect the Hera system to be on the market for another five or six years.

The team expects to start animal trials in about 15 monthsโ€™ time, and will likely embark on another capital raise ahead of that.

Based on those results, the startup will move onto human clinical trials, which will require more funding again.

That said, Williams says if a large corporate in the hearing industry wanted to set up a strategic partnership, things could move more quickly.

โ€œItโ€™s a very interesting market, because there are only three major players, but the market is huge and itโ€™s very underserved,โ€ she says.

โ€œSo it will be interesting to see what the response from the market will be.โ€

The power of the accelerator

Williams advises other research-based startups to look for an accelerator program.

The MedTechโ€™s Got Talent accelerator provided Hemideina with seed funding allowing the founders to explore the idea further, and โ€œthat was what launched usโ€, she says.

However, itโ€™s also about โ€œgetting the team around youโ€.

Both Williams and Lomas come from science and research backgrounds, and had never run a business before.

Accelerator programs can give you โ€œa lot of the foundational trainingโ€, Williams says, as well as helping you connect with networks applicable to your business.

โ€œItโ€™s about identifying who can help you and getting the people around you to drive you forward,โ€ she says.

NOW READ:ย Sydney startup secures grant to develop adorable robot helping sick kids at home

NOW READ:ย Biotech startup Paragen Bio raises $6 million for its work fighting diseases with parasitic worms